Skip to main content
OpenTrials
Completed

NCT Number: NCT01361620

Genotypic and Phenotypic Correlates of Resistance to Aspirin

The study seeks to identify genomic markers associated with aspirin resistance.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Platelet Dysfunction Due to Aspirin

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

GWU Medical Faculty Associates

Washington D.C., District of Columbia, 20037, United States

About this study

Not desired

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Volunteers 40 to 80 years old willing to sign consent and take 81 mg of aspirin for 7 - 10 days and return for laboratory testing.

Exclusion criteria

  • Patient requiring more than 81 mg aspirin daily
  • Known GI bleeding attributed to ASA
  • Active peptic ulcer disease or history within the last year
  • Known aspirin allergy
  • Current use of:
  • warfarin,
  • heparin,
  • NSAIDs (except aspirin),
  • clopidogrel,
  • dipyridamole,
  • fish-oil/omega 3 supplements,
  • Women of childbearing potential who are pregnant, planning to become pregnant or nursing.

Treatment and study plan

Aspirin

Drug

aspirin 81mg, 7-10 days

Primary outcomes

  1. Whole Blood Coagulation

    Time frame: Single measurement at 7-10 days after beginning aspirin

    Whole blood coagulation after stimulation with arachidonic acid, as measured in the VerifyNow Aspirin system (Accumetrics). Aspirin response units (ARU) are the residual coagulation present in patients taking aspirin. The higher the ARU, the greater residual coagulation (resistance) to the aspirin effect.

Sponsors and collaborators

Lead sponsor

George Washington University

Other

Registry information

Official study title

Genotypic and Phenotypic Correlates of Resistance to Anti-platelet Actions of Aspirin in an At-risk Patient Population and in the General Population

Acronym: ARSENAL

Important dates

Study start
2007
Primary completion
2011
Study completion
2011
First posted
May 27, 2011
Registry last updated
Dec 16, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.